What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

1. Discovering the role of microRNAs and exosomal microRNAs in chest and pulmonary diseases: a spotlight on chronic obstructive pulmonary disease.Molecular genetics and genomics : MGG · 2024
   Review
2. miR-223: a key regulator of pulmonary inflammation.Frontiers in medicine · 2023
   Review
3. Silencing of Long Non-Coding RNA HOTAIR Alleviates Epithelial-Mesenchymal Transition in Pancreatic Cancer via the Wnt/β-Catenin Signaling Pathway.Cancer management and research · 2021
   Article
4. A combination of four serum miRNAs for screening of lung adenocarcinoma.Human cell · 2020
   Article
5. Aerobic Exercise Inhibits CUMS-Depressed Mice Hippocampal Inflammatory Response via Activating Hippocampal miR-223/TLR4/MyD88-NF-κB Pathway.International journal of environmental research and public health · 2020
   Article
6. Role of the NLRP3 Inflammasome: Insights Into Cancer Hallmarks.Frontiers in immunology · 2020
   Review
7. miR-223: A Key Regulator in the Innate Immune Response in Asthma and COPD.Frontiers in medicine · 2020
   Review
8. MiR-223 regulates autophagy associated with cisplatin resistance by targeting FBXW7 in human non-small cell lung cancer.Cancer cell international · 2020
   Article
9. NLRP3 inflammasome inactivation driven by miR‑223‑3p reduces tumor growth and increases anticancer immunity in breast cancer.Molecular medicine reports · 2019
   Article
10. MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop.Journal of experimental & clinical cancer research : CR · 2019
    Article
11. MicroRNA 615-3p Inhibits the Tumor Growth and Metastasis of NSCLC via Inhibiting IGF2.Oncology research · 2019
    Article
12. MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin.OncoTargets and therapy · 2019
    Article
13. Diagnostic Value of Plasma MicroRNAs for Lung Cancer Using Support Vector Machine Model.Journal of Cancer · 2019
    Article
14. Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer.Oncology letters · 2018
    Article
15. Expression of miR-634 in gastric carcinoma and its effects on proliferation, migration, and invasion of gastric cancer cells.Cancer medicine · 2018
    Article
16. Application of serum microRNA-9-5p, 21-5p, and 223-3p combined with tumor markers in the diagnosis of non-small-cell lung cancer in Yunnan in southwestern China.OncoTargets and therapy · 2018
    Article
17. MicroRNA Roles in the Nuclear Factor Kappa B Signaling Pathway in Cancer.Frontiers in immunology · 2018
    Review
18. MiR-185 inhibits tumor growth and enhances chemo-resistance via targeting SRY-related high mobility group box transcription factor 13 in non-small-cell carcinoma.American journal of translational research · 2018
    Article
19. Low Frequency Magnetic Fields Induce Autophagy-associated Cell Death in Lung Cancer through miR-486-mediated Inhibition of Akt/mTOR Signaling Pathway.Scientific reports · 2017
    Article
20. MicroRNA-223 alleviates lipopolysaccharide-induced PC-12 cells apoptosis and autophagy by targeting RPH1 in spinal cord injury.International journal of clinical and experimental pathology · 2017
    Article

Corrections and comments

• Retraction · 2020-11-01Investigation by Third Party · Notice - Limited or No Information · Paper Mill · Removed · · see also: https://pubpeer.com/publications/175DA57BF305AA91A4FD7769030F11
• Retracted

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as